By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 185 % ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

Krishnamurti helps bring a new federal program for expanding treatment access for Medicaid patients to Connecticut ...

At 22, Daniel Cressy is making history as Louisiana’s first sickle cell gene therapy patient. The treatment could be a cure ...

He recently had the first of two six-hour procedures at Manning Family Children's Hospital to collect his stem cells in order to edit them.

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

The Dow Jones Industrial Average rose 585.4 points, or 1.34%, at the open to 44173.64. The S&P 500 rose 91.93 points, or 1.47 ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...